<DOC>
	<DOCNO>NCT00505778</DOCNO>
	<brief_summary>The purpose study compare efficacy maintain remission ulcerative colitis daily ( QD ) Asacol regimen divide , twice daily ( BID ) Asacol dose regimen .</brief_summary>
	<brief_title>A Comparison Once Day Dose Compared 2 Doses/Day</brief_title>
	<detailed_description>Currently , US , Asacol therapy indicate divided dos maintenance remission ulcerative colitis 1.6 g/day . A daily dose potentially beneficial patient physician alike . This study answer follow question daily dosing : ( 1 ) efficacy differ daily twice daily dose , ( 2 ) patient prefer daily dose regimen , ( 3 ) compliance well ? This study confirm whether benefit daily dose beyond increase convenience . In order understand QD regimen compare BID `` real life '' practice setting , patient remain total daily dose Asacol ( 1.6 g/day 2.4 g/day ) maintain remission , assign either QD BID regimen . This investigator-blinded study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Documented history ulcerative colitis successfully maintain remission least 3 month prior study entry At least one flare past 18 month Utilizing stable maintenance dose oral Asacol 1.6 g/day 2.4 g/day ( stable dose define dose past 3 month ) Females must postmenopausal surgically sterile negative urine pregnancy test practice acceptable contraception History current renal disease History hepatic disease History allergy hypersensitivity salicylate , aminosalicylates Treatment immunomodulatory therapy , biologic therapy corticosteroid within 90 day screen Received antidiarrheal , antispasmodic , antibiotic within 1 month screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>